Travancore–Cochin

Ermium Therapeutics Extends Its Initial €6,3 M Funding to €12,3 M to Further Advance Breakthrough Auto-Immune Disease Therapeutics

Retrieved on: 
Thursday, June 30, 2022
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Science, Patient, CEO, Biotechnology, USD, SLE, Dermatomyositis, GPCR, CXCR4, Intellectual property, CNRS, Health, Venture capital, Degenerative disease, Kurma, Investment, Therapy, EUR, Travancore–Cochin, Program, Pharmaceutical industry, Vaccine

Ermium Therapeutics, a Paris-based biotech company developing innovative health products for auto-immune diseases, announced today the extension of its initial funding of 6.3 M to 12.3 M with Kurma Partners and Fountain Healthcare Partners.

Key Points: 
  • Ermium Therapeutics, a Paris-based biotech company developing innovative health products for auto-immune diseases, announced today the extension of its initial funding of 6.3 M to 12.3 M with Kurma Partners and Fountain Healthcare Partners.
  • Fountain Healthcare Partners, a transatlantic life science investor, is joining and widening the Ermium Therapeutics initial investment syndicate composed of Kurma Partners, Eurazeo, Domain Therapeutics, and Erganeo.
  • We were very impressed by the work accomplished by the team at Ermium Therapeutics.
  • About Ermium Therapeutics: Ermium Therapeutics, a discovery stage company, was founded in June 2019 by Dr Jean-Philippe Herbeuval (CNRS Universit Paris Cit), Kurma Partners, Domain Therapeutics, and Erganeo.

T.H.A.C Announces the Acquisition of an International Patent on Its Drug Candidate ALF-5755 For the Early Treatment of Type 2 Diabetes Mellitus and Relative to the Gut Microbiota Composition

Retrieved on: 
Monday, September 27, 2021
Health, Diabetes, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, THAC, Patent, Infection, EADS, University, Peripheral neuropathy, Public sector, Roy Taylor (scientist), French Government of the Hundred Days, COVID-19, Pandemic, Ageing, Dysbiosis, Patient, ADA, Louis Pasteur, Lists of diseases, CSIS, INRA, Diabetes, Disease, CEO, Industry, Acquisition, University of Paris, Company, Growth, Microbiota, University of South Florida, Science, Global Virus Network, Human, Travancore–Cochin, Research, Obesity, Insulin, Hospital, Â, Sanofi, Insulin resistance, R, SA, Doctor of Philosophy, INSERM, Degenerative disease, Pharmaceutical industry, Management

This patent protects the drug candidate of THAC and its use for the protection of oxygen sensitive bacteria, for example in the gut microbiota.

Key Points: 
  • This patent protects the drug candidate of THAC and its use for the protection of oxygen sensitive bacteria, for example in the gut microbiota.
  • It allows to reinforce our robust patent portfolio as well as to develop a competitive oral formulation for our product.
  • With this patent, we accelerate our development, and we strengthen our competitive position on the market.
  • The dysbiosis, disequilibrium of the gut flora in humans, is characterized by complex changes in the microbiota and its various micro-organisms.